{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:40:03Z","timestamp":1777419603116,"version":"3.51.4"},"reference-count":47,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T00:00:00Z","timestamp":1258416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review pharmacologic, pharmacokinetic, efficacy, and safety data for fesoterodine and determine its role in the treatment of overactive bladder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A MEDLINE search (1966\u2013July 2009) was conducted using the key words fesoterodine, tolterodine, muscarinic receptor antagonist, anticholinergic, overactive bladder, urge incontinence, efficacy, safety, adverse effect, pharmacology, pharmacokinetic, and receptor binding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All articles written in English that were identified from the data sources were evaluated, prioritizing randomized, controlled trials with human data. The references of published articles that we identified were examined for any additional studies appropriate for the review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Fesoterodine, a competitive muscarinic receptor antagonist, is converted to its active metabolite, 5-hydroxymethyltolterodine, by nonspecific esterases, bypassing the cytochrome P450 system. Two randomized controlled Phase 3 trials examined the safety and efficacy of fesoterodine In the treatment of overactive bladder. Fesoterodine was found to produce significant improvements in the treatment of overactive bladder symptoms compared with placebo. Post hoc analysis of these trials demonstrated significant improvements in health-related quality of life in patients with overactive bladder. Only one study included tolterodine, and direct comparisons between fesoterodine and tolterodine were not conducted. The most common treatment-emergent adverse effects associated with fesoterodine included dry mouth, constipation, urinary tract infection, and headache.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Fesoterodine appears to be effective and generally safe for the treatment of overactive bladder. The efficacy and safety of fesoterodine in overactive bladder treatment seem to be at least similar to that of tolterodine. Although additional comparative trials are needed, based on available data, it does not appear that fesoterodine provides a substantial advantage over extended-release tolterodine in either efficacy or safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1m308","type":"journal-article","created":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T23:13:33Z","timestamp":1258499613000},"page":"1992-2000","source":"Crossref","is-referenced-by-count":4,"title":["Formulary Forum: Fesoterodine for the Treatment of Overactive Bladder"],"prefix":"10.1177","volume":"43","author":[{"given":"Maria","family":"Tzefos","sequence":"first","affiliation":[{"name":"School of Pharmacy, Wingate University, Wingate, NC; Clinical Pharmacist, Cabarrus Family Medicine, Harrisburg, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Dolder","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Wingate University; Clinical Pharmacist, Carolinas Medical Center-Northeast, Concord, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline L","family":"Olin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Wingate University; Clinical Pharmacist, Matthews Health Clinic, Matthews, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,11,17]]},"reference":[{"key":"bibr1-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.125704"},{"key":"bibr2-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0b013e32830fe38c"},{"key":"bibr3-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07601.x"},{"key":"bibr4-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01714.x"},{"key":"bibr5-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.03076.x"},{"key":"bibr6-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.05.015"},{"key":"bibr7-aph.1M308","doi-asserted-by":"publisher","DOI":"10.4065\/78.6.687"},{"key":"bibr8-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.11.008"},{"key":"bibr9-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.00987.x"},{"key":"bibr10-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000570"},{"key":"bibr11-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.7.999"},{"key":"bibr12-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.145508"},{"key":"bibr13-aph.1M308","unstructured":"Product information. Toviaz (fesoterodine fumarate). New York: Pfizer Inc., January 2007 (revised November 2008)."},{"key":"bibr14-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.10.1787"},{"key":"bibr15-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00540-7"},{"key":"bibr16-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06258.x"},{"key":"bibr17-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00563-5"},{"key":"bibr18-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07358.x"},{"key":"bibr19-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1997.tb02064.x"},{"key":"bibr20-aph.1M308","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46556"},{"key":"bibr21-aph.1M308","first-page":"125","volume":"51","author":"Pahlman I","year":"2001","journal-title":"Arzneimittelforschung"},{"key":"bibr22-aph.1M308","unstructured":"Fesoterodine (Toviaz) for overactive bladder. Med Lett Drugs Ther 2009;51:34\u20135."},{"key":"bibr23-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009332434"},{"key":"bibr24-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0648-1"},{"key":"bibr25-aph.1M308","unstructured":"Product information. Detral LA (tolterodine tartrate extended release). Kalamazoo, MI: Pharmacia and Upjohn Co., January 2003 (revised March 2008)."},{"key":"bibr26-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.07.009"},{"key":"bibr27-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.033"},{"key":"bibr28-aph.1M308","author":"Chapple C.","journal-title":"Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (abstract)"},{"key":"bibr29-aph.1M308","unstructured":"NittiVVM, KreitmanL. Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. PDF 2005. http:\/\/icsoffice.org\/publications\/2005\/PDF0306.pdf (accessed 2009 Apr 29)."},{"key":"bibr30-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.12.017"},{"key":"bibr31-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07907.x"},{"key":"bibr32-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02035.x"},{"key":"bibr33-aph.1M308","first-page":"1044","volume":"57","author":"Liberman JN","year":"2001","journal-title":"community-based survey. Urology"},{"key":"bibr34-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-002-0301-4"},{"key":"bibr35-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07710.x"},{"key":"bibr36-aph.1M308","first-page":"S608","volume":"8","author":"Kelleher CJ","year":"2002","journal-title":"Am J Manag Care"},{"key":"bibr37-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"bibr38-aph.1M308","unstructured":"Product information. Vesicare (solifenacin succinate). Norman, OK: Astellas Pharma Technologies, 2005 (revised November 2008)."},{"key":"bibr39-aph.1M308","unstructured":"Product information. Enablex (darifenacin). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2006 (revised June 2008)."},{"key":"bibr40-aph.1M308","unstructured":"Product information. Detrol (tolterodine tartrate). New York: Pharmacia and Upjohn Company, 2008 (revised March 2008)."},{"key":"bibr41-aph.1M308","unstructured":"Product information. Sanctura (trospium chloride). Lexington, MA and East Brunswick, NJ: Esprit Pharmaceuticals and Indevus Pharmaceuticals Inc., December 2006."},{"key":"bibr42-aph.1M308","unstructured":"Product information. Ditropan XL (oxybutynin chloride extended release). Mountain View, CA: ALZA Corporation, 1998 (revised February 2008)."},{"key":"bibr43-aph.1M308","unstructured":"Product information. Oxytrol (oxybutynin transdermal system). Corona, CA: Watson Pharmaceuticals Inc., May 2006."},{"key":"bibr44-aph.1M308","unstructured":"Product information. Gelnique (oxybutynin chloride gel). Corona, CA: Watson Pharmcaceuticals Inc., January 2009."},{"key":"bibr45-aph.1M308","unstructured":"Product information. Ditropan (oxybutynin chloride). Kansas City, MO: Aventis Pharmaceuticals, revised September 2003."},{"key":"bibr46-aph.1M308","unstructured":"Product information. Sanctura XR (trospium chloride extended release). Irvine, CA: Allergan, Inc., December 2006."},{"key":"bibr47-aph.1M308","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0b013e32831a6ff3"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:11:15Z","timestamp":1777374675000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1M308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,17]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1345\/aph.1M308"],"URL":"https:\/\/doi.org\/10.1345\/aph.1m308","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,17]]}}}